Yokoyama et al. (Yokoyama et al., 2017) suggested a novel combination therapy targeting Bcl-2/Bcl-xL and PARP, leading to greater cytotoxicity against high-grade serous ovarian cancer cells by inducing apoptosis. Here, BCL2L1 is linked to ovarian serous adenocarcinoma.